A rare case of suspected lupus erythematosus panniculitis as the presenting skin feature of juvenile dermatomyositis: A case report

Dylan C Ginter1, Michele L Ramien2, Marie-Anne Brundler3, Laura C Swaney4, Paivi MH Miettunen5 and Nadia JC Luca5

Abstract
Juvenile dermatomyositis is a rare autoimmune myopathy of childhood, associated with systemic vasculopathy, primarily affecting the capillaries.1 Panniculitis is seen histologically in about 10% of patients with dermatomyositis; however, its clinical presentation is rare, with only 30 cases presented in the literature to date. The histopathology overlaps with other inflammatory disease states, and is almost identical to the panniculitis seen in lupus erythematosus panniculitis. In the cases with both panniculitis and dermatomyositis, skin and muscle inflammation is usually the first clinical manifestation. We present a case of a 16-year-old female with panniculitis as the initial presenting feature of juvenile dermatomyositis in the context of a prior diagnosis of indeterminate colitis.

Keywords
Juvenile dermatomyositis, lupus erythematosus panniculitis, inflammatory bowel disease, lupus panniculitis, panniculitis

Introduction
Juvenile dermatomyositis (JDM) is a rare autoimmune myopathy of childhood, associated with systemic vasculopathy, primarily affecting the capillaries.1 The disease is characterized by cutaneous findings, such as heliotrope rash and Gottron’s papules, proximal muscle weakness, elevated creatinine kinase, and endomysial infiltration of mononuclear cells surrounding myofibers.2 JDM has an annual incidence rate of two to three cases per one million children, with females affected two to five times more than males.1 Current standard treatment for JDM includes high-dose systemic steroids, methotrexate (MTX), and hydroxychloroquine for initial treatment, and intravenous immunoglobulin (IVIG) and/or cyclophosphamide or biologic therapies for refractory cases.3 Panniculitis has rarely been described in the setting of dermatomyositis (DM) in adult and pediatric patients despite 10% of patients having subclinical evidence of panniculitis on muscle biopsy.4 In the cases reported, myositis almost always occurs before the panniculitis manifests.5-7 The histopathological findings of the panniculitis in JDM overlap with other inflammatory diseases, notably lupus erythematosus panniculitis (LEP). We present the case of a 16-year-old female who developed panniculitis as the first manifestation of JDM, thought initially to be LEP, in the context of a prior diagnosis of inflammatory bowel disease (IBD).

Case report
The patient initially presented with fatigue, bloody stools, and low-grade fevers at the age of 14.5 years, and was diagnosed with atypical indeterminate colitis based on rectal biopsy findings. She was trialed on multiple formulations of
mesalazine, oral budesonide, and oral prednisone, before symptom remission with a colon-specific oral mesalazine and rectal mesalazine. She was referred to pediatric rheumatology and dermatology clinics at age 16 years for new concerns of bruising and leg pain without any obvious injury, associated with underlying painful, firm palpable lesions on her thighs and upper arms (Figure 1). These lesions were suspected to be erythema nodosum in the context of her IBD diagnosis, but the distribution affecting the proximal limbs was atypical. Her rheumatologic review of systems was negative at that time, and her investigations demonstrated positive antinuclear antibody (ANA) $\geq 1:640$, anti-neutrophil cytoplasmic antibody with perinuclear pattern (P-ANCA), myeloperoxidase antibody (MPO) 1.8 Antibody Index Units (AI) (0.0–0.9 AI), and centromere B 1.4 AI (0.0–0.9 AI). Anti-ds DNA antibody and rheumatoid factor were negative; C3, C4, and immunoglobulins (Igs) were normal. A deep skin biopsy including the fascia was performed, and the pathology was consistent with LEP (Figure 2). She was started on hydroxychloroquine 300 mg PO daily with improvement.

After 3 months of treatment, she developed periorbital edema with suborbital ecchymosis, facial rash in the malar distribution, myalgia, arthralgia, worsening fatigue, and

**Figure 1.** Multiple painful gray-brown subtly indurated and depressed round nodules most prominent on the anterior (a) and lateral thighs bilaterally (b and c), initially diagnosed as lupus erythematosus panniculitis on skin biopsy before other clinical manifestations of juvenile dermatomyositis presented.

**Figure 2.** Deep skin and subcutaneous biopsy of the lateral thigh: scanning magnification (a) shows a lobular panniculitis and a patchy superficial and deep dermal perivascular, perifollicular, and periadnexal lymphoplasmacytic inflammatory infiltrate without accompanying interface or epidermal changes (Hematoxylin & Eosin $\times 20$). Higher magnification (b) shows the lymphoplasmacytic inflammation within lobules of subcutaneous fat and small foci of fat necrosis (Hematoxylin & Eosin $\times 100$).
30 min of morning stiffness in her fingers with marked dilated nailfold capillaries. She was trialed on a 5-day course of 5 mg oral prednisone with no improvement so increased to 50 mg daily dosing with some improvement. Repeat investigations showed positive RNP-A at 1.3 AI (0.0–0.9 AI), medium positive anti-histone antibody, creatine kinase (CK) 312 (20–300 U/L), and Epstein–Barr virus (EBV) IgM positive, IgG negative. It was thought she had an intercurrent EBV infection with the Hoagland sign as an explanation for the periorbital edema, and thus, her steroids were tapered. At lower doses of oral prednisone, she had increased myalgias, muscle weakness particularly with lifting arms overhead, and worsening periorbital edema with more prominent malar rash. Her myositis antibody panel was negative. As her weakness began to progress, her prednisone dose was increased to 60 mg PO daily when she became severely unwell with fever, hypotension, and profound weakness, resulting in an admission to the intensive care unit. A magnetic resonance imaging (MRI) of her muscles demonstrated widespread myositis (Figure 3). A muscle biopsy showed classic features of immune myopathy with perimysial pathology that was most consistent with the clinical entity of JDM.

She was treated with IVIG 2 g/kg, IV methylprednisolone 1 g daily for 5 days, MTX 25 mg subcutaneous weekly, and remained on hydroxychloroquine 300 mg daily. Her symptoms improved significantly throughout her stay and she was discharged after 11 days in hospital.

Discussion

Our patient demonstrates a rare occurrence of lobular panniculitis as a first dermatologic feature of JDM. Our initial diagnosis of LEP was reasonable, as the histopathologic findings of DM panniculitis are largely identical to those of lupus panniculitis, demonstrating the challenge of distinguishing between these entities histopathologically. LEP is a rare form of chronic cutaneous lupus erythematosus (LE), characterized by inflammation of the subcutaneous fat, presenting in 1%–3% of patients with cutaneous LE. The disease manifests as indurated plaques or nodules usually on the proximal extremities and trunk, which are tender or painful, may progress to calcifications or ulcerations, and frequently result in lipoatrophy upon resolution. As with DM panniculitis, histopathology demonstrates dermal perivascular infiltrates of mononuclear cells with lobular panniculitis, hyaline fat necrosis, paraseptal lymphoid aggregates, and lymphocytic vasculitis. Usually, LEP and DM panniculitis can be differentiated based on the broader clinical picture. When the patient started demonstrating significant myositis, the diagnosis of JDM was considered more likely. Since her weakness worsened with the initial steroid wean, it was unlikely that her presentation was due to steroid-induced myopathy. The patient’s periorbital edema was another early cutaneous finding, which has been reported as part of the clinical presentation of JDM in case reports only, but is not one of the classic cutaneous manifestations of JDM.

Our patient had another unique feature, with her prior diagnosis of indeterminate colitis and treatment with mesalazine. Mesalazine has been associated with drug-induced lupus. Anti-histone antibodies are present in more than 95% of cases of drug-induced lupus, but can also occur in up to 80% of patients with idiopathic lupus. Interestingly, anti-histone antibodies have also been reported in up to 17% of patients with DM. It is known that IBD and DM can occur together. In adult studies, the incidence of DM is higher in patients with ulcerative colitis (UC) compared to control groups, and the presence of UC may actually be a risk factor for DM. Given that the entire clinical picture is compatible with JDM, and that there are no reports of mesalazine inducing JDM, her disease was likely not
drug-induced. As a precaution, our patient discontinued mesalazine and continued MTX, high-dose prednisone, IVIG, and hydroxychloroquine to treat her colitis, skin manifestations, and myositis. At time of publication—3 months after her acute presentation—her panniculitis has resolved with lipoatrophy, she has normal functional muscle strength and her IBD symptoms are well controlled. This case is an example of overlapping inflammatory diseases occurring in a single patient, and the complex diagnostic dilemma of panniculitis as a presenting feature of evolving JDM.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

Informed consent
Informed consent for information and images to be published was provided by the patient.

ORCID iD
Dylan C Ginter https://orcid.org/0000-0002-6949-1085

References
1. Feldman BM, Rider LG, Reed AM, et al. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. *Lancet* 2008; 371(9631): 2201–2212.
2. Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. *Annals of the Rheumatic Diseases* 2017; 76(12): 1955–1964.
3. Stringer E, Bohnsack J, Bowyer SL, et al. Treatment approaches to juvenile dermatomyositis (JDM) across North America: the childhood arthritis and rheumatology research alliance (CARRA) JDM treatment survey. *J Rheumatol* 2010; 37(9): 1953–1961.
4. Castillo RL and Femia AN. Covert clues: the non-hallmark cutaneous manifestations of dermatomyositis. *Ann Transl Med* 2021; 9(5): 346.
5. Polcari IC and Stein SL. Panniculitis in childhood. *Dermatol Ther* 2010; 23(4): 356–367.
6. Salman A, Kasapcopur O, Ergun T, et al. Panniculitis in juvenile dermatomyositis: report of a case and review of the published work. *J Dermatol* 2016; 43(8): 951–953.
7. Yoo JY, Jo SJ and Cho KH. Lupus panniculitis with combined features of dermatomyositis resulting in severe lipoatrophy. *J Dermatol* 2004; 31(7): 552–555.
8. Inokuchi R, Iida H, Ohta F, et al. Hoagland sign. *Emerg Med J* 2014; 31(7): 561.
9. Braunstein I and Werth VP. Update on management of connective tissue panniculitides. *Dermatol Ther* 2012; 25(2): 173–182.
10. Santos-Briz A, Calle A, Linos K, et al. Dermatomyositis panniculitis: a clinicopathological and immunohistochemical study of 18 cases. *J Eur Acad Dermatol Venereol* 2018; 32(8): 1352–1359.
11. Park HS, Choi JW, Kim B, et al. Lupus erythematosus panniculitis: clinicopathological, immunophenotypic, and molecular studies. *Am J Dermatopathol* 2010; 32(1): 24–30.
12. Peters MS and Daniel Su WP. Lupus erythematosus panniculitis. *Medical Clinics of North America* 1989; 73(5): 1113–1126.
13. Crowson AN and Magro C. The cutaneous pathology of lupus erythematosus: a review. *J Cutan Pathol* 2001; 28(1): 1–23.
14. Gupta Y and Gupta A. Glucocorticoid-induced myopathy: pathophysiology, diagnosis, and treatment. *Indian J Endocrinol Metab* 2013; 17(5): 913–916.
15. Sevigny GM and Mathes BM. Periorbital edema as the presenting sign of juvenile dermatomyositis. *Pediatr Dermatol* 1999; 16(1): 43–45.
16. Katsanos KH, Voulgari PV and Tsianos EV. Inflammatory bowel disease and lupus: a systematic review of the literature. *J Crohn Colitis* 2012; 6(7): 735–742.
17. Yung RL, Johnson KJ and Richardson BC. New concepts in the pathogenesis of drug-induced lupus. *Lab Invest* 1995; 73(6): 746–759.
18. Kubo M, Ihn H, Yazawa N, et al. Prevalence and antigen specificity of anti-histone antibodies in patients with polymyositis/dermatomyositis. *J Invest Dermatol* 1999; 112(5): 711–715.
19. Meneghel A, Zulian F, Martini G, et al. Ischemic ulcerative colitis in juvenile dermatomyositis. *J Pediatr Gastroenterol Nutr* 2009; 49(5): 549.
20. Tseng C-C, Chang S-J, Liao W-T, et al. Increased cumulative incidence of dermatomyositis in ulcerative colitis: a nationwide cohort study. *Sci Rep* 2016; 6(1): 28175.